INOVIQ LTD — Capital/Financing Update 2019

Jun 17, 2019

==> picture [155 x 46] intentionally omitted <==

18 JUNE 2019

ENTITLEMENT ISSUE CLEANSING NOTICE

This notice is given by BARD1 Life Sciences Limited (ASX: BD1) ( Company ) under section 708AA(2)(f) of the Corporations Act 2001 (Cth) ( Act ), as modified by the Australian Securities and Investments Commission ( ASIC ).

The Company announced today a partially underwritten non-renounceable pro rata entitlement offer to shareholders with a registered address in Australia, New Zealand, Switzerland and Hong Kong of 1 fully paid ordinary share in the Company ( New Share ) for every 10 fully paid ordinary shares in the Company held on the record date of 5.00pm (AWST) on 21 June 2019, at an issue price of $0.02 per New Share, to raise approximately $2.5 million (before costs) ( Entitlement Issue ).

The Company also announced today the completion of a placement, by which the Company has raised approximately $5 million (before costs) by the issue of 248,500,000 fully paid ordinary shares in the Company at an issue price of $0.02 per share.

The Company advises that:

1. the Company will offer the New Shares under the Entitlement Issue without disclosure to investors under Part 6D.2 of the Act;

2. this notice is being given under section 708AA(2)(f) of the Act as modified by ASIC;

3. as at the date of this notice, the Company has complied with:

   • (a) the provisions of Chapter 2M of the Act as they apply to the Company; and

   • (b) section 674 of the Act;

4. as at the date of this notice, there is no 'excluded information' of the type referred to in section 708AA(8) and 708AA(9) of the Act which is required to be disclosed by the Company; and

5. the potential effect that the Entitlement Issue will have on the control of the Company, and the consequences of that effect, will depend on a number of factors, including investor demand and existing shareholdings. As the Entitlement Issue is a pro rata issue, and given the current level of holdings of substantial holders (based on substantial holder notices that have been given to the Company and lodged with ASX before the date of this announcement), the Entitlement Issue is not expected to have any material effect on the control of the Company and, as a result, there is not expected to be any consequences flowing from that effect.

• ENDS -

FOR MORE INFORMATION PLEASE CONTACT:

Peter Gunzburg Dr Leearne Hinch Chairman CEO E peter@bard1.com E leearne@bard1.com M +61 400 414 416

ABOUT BARD1 LIFE SCIENCES LTD

BARD1 Life Sciences Ltd (ASX:BD1) is an Australian medical technology company focused on developing and commercialising non-invasive diagnostic tests for early detection of cancer. BARD1 owns a proprietary tumour marker platform with potential diagnostic and therapeutic applications across

BARD1 Life Sciences Limited (ABN 58 009 070 384) Registered Office | Suite B1, Tempo Building, 431 Roberts Road, Subiaco WA 6008, Australia P +618 9381 9550 | F +618 9388 7559 | E info@bard1.com | W www.bard1.com

BARD1 | ASX Release

2

multiple cancers. The pipeline includes BARD1 autoantibody tests in development for early detection of breast, ovarian and lung cancers. BARD1’s vision is to detect cancer early and save lives. For more information on BARD1, see www.bard1.com.

BARD1 LSL | ASX Release